taken from the 2022 annual report:The broad research partnership...

taken from the 2022 annual report:

The broad research partnership is material to Imugene as it includes the development of Imugene’s onCARlytics CD19 oncolytic virus licensed from the City of Hope® with Celularity’s allogeneic CAR T-cell therapy (CyCART-19) and has the potential to become a new approach to improve outcomes for patients with solid tumours.

The research collaboration agreement, effective 5 August 2021, has an initial term of 12 months. Following the successful completion
of the pre-clinical research, the parties will negotiate in good faith a collaboration agreement on commercially reasonable terms.

most likely nothing